Immuron Limited (IMRN) Stock Score, Valuation & Financial Research
Immuron Limited is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 33/100.
Quick answer for IMRN
Immuron Limited currently has a Wall Street Score of 33/100. The stored market price is $1.45. Its financial score is 25/100. Its valuation score is 0/100. The latest WSS change is +0.2 points. These figures are a research snapshot, not a buy or sell recommendation.
What Immuron Limited does
Immuron Limited is a biopharmaceutical company focused on the discovery, development, and global commercialization of polyclonal antibodies, with operations spanning Australia, the United States, and other international markets. The company's activities are structured into two key segments: Research and Development, and Hyperimmune Products. Currently, Immuron markets two key products. Travelan is an over-the-counter (OTC) medicine that helps reduce the risk of traveler's diarrhea and lessens symptoms of minor gastrointestinal issues, while also serving as a dietary supplement for digestive tract protection. Its second product, Protectyn, is an immune supplement formulated to support healthy digestive function and liver health. In its pipeline, an advanced formulation of Travelan (IMM-124E) is undergoing Phase III clinical trials. This variant is being developed not only to further reduc
IMRN financial snapshot
- Wall Street Score:
- 33/100
- Current price:
- $1.45
- Market capitalization:
- $9.3M
- Revenue:
- $9.2M
- Net income:
- $-6.0M
- Free cash flow:
- $-4.3M
- Cash:
- $7.0M
- Total debt:
- $83K
- EPS:
- -0.64
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 53/100
What stands out
- Reported year-over-year revenue growth is +0.8%.
- Free cash flow is $-4.3M, showing cash burn in the current stored period.
- The balance sheet shows $7.0M of cash versus $83K of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +0.2 points: IMRN increased 0.2 points because overall fundamentals improved.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research IMRN
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.